Randomized, Multicenter Study of Tolerability and Efficacy of Modified Combinations of Bortezomib, Dexamethasone and Cyclophosphamide in Previously Untreated Multiple Myeloma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

09 Sep 2019 New trial record
01 Sep 2019 Results (data cut off: August 1, 2018; n=85) assessing efficacy and safety published in the Journal of Cancer Research and Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com